VEGFA and renal cell carcinoma: Over the past decade, RCC-associated therapeutic options have changed from nonspecific immune pathways (cytokines) to targeted therapy against vascular endothelial growth factor (VEGF) then to recent novel immunotherapeutic agents [7].